114798-32-2

Usage

Uses

Used in Pharmaceutical Industry:
[1,1'-Biphenyl]-2-carboxylic acid,4'-[[2-(1E)-1-buten-1-yl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]is used as a pharmaceutical compound for its potential therapeutic applications. [1,1'-Biphenyl]-2-carboxylicacid,4'-[[2-(1E)-1-buten-1-yl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-'s unique structure may allow it to interact with various biological targets, making it a candidate for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, [1,1'-Biphenyl]-2-carboxylic acid,4'-[[2-(1E)-1-buten-1-yl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]is used as a chemical building block for the synthesis of novel agrochemicals. Its structural diversity may contribute to the development of new pesticides, herbicides, or other agricultural products.
Used in Materials Science:
[1,1'-Biphenyl]-2-carboxylic acid,4'-[[2-(1E)-1-buten-1-yl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]is used as a component in the development of advanced materials. Its unique chemical properties may be harnessed to create new materials with specific characteristics, such as improved mechanical strength, thermal stability, or chemical resistance.

Upstream product

• 114772-69-9 1-[(2'-Carbomethoxybiphenyl-4-yl)methyl]-2-(1-trans-butenyl)-4-chloro-5-hydroxymethylimidazole 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 624-31-7 4-tolyl iodide 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 7148-03-0 o-tolylbenzoic acid 
• 114772-34-8 methyl 4'-methylbiphenyl-2-carboxylate 
• 74201-13-1 N-(2-hydroxy-1,1-dimethyl)-2-methoxybenzamide 
• 114772-38-2 Methyl 4'-(bromomethyl)biphenyl-2-carboxylate 
• 84392-32-5 4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole 
• 114772-68-8 2-(1-trans-butenyl)-1-<(2'-carbomethoxybiphenyl-4-yl)methyl>-4-chloroimidazole-5-carboxaldehyde 
• 114772-67-7 1-[(2'-carbomethoxybiphenyl-4-yl)-methyl]-2-(1-bromobutyl)-4-chloroimidazole-5-carboxaldehyde 
• 114772-43-9 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-methoxycarbonyl-1,1'-biphenyl-4-yl)methyl]-1H-imidazole 
• 114772-66-6 2-butyl-4-chloro-5-formyl-1-[(2'-methoxycarbonyl-1,1'-biphenyl-4-yl)methyl]-1H-imidazole 
• 579-75-9 2-Methoxybenzoic acid 

Relevant academic research and scientific papers

Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients

The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2′-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.

INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES

This invention relates to a novel method of using an Angiotensin II antagonist for the improvement of insulin sensitivity alone or in conjunction with the treatment of hypertension. Angiotensin II antagonists such as the class of substituted imidazoles represented by formula I: STR1 and specifically by Losartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-yl]methyl]-5-(hydroxymethyl)imidazole potassium salt.

Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles

A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II antagonist. This method of treatment can be used in conjunction with the treatment of hypertension. Substituted imidazoles such as STR1 are useful as angiotensin II receptor antagonists for this method of treatment. A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II receptor antagonist in combination with an HMG-Co A reductase inhibitor. A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II receptor antagonist in combination with an HMG-Co A reductase inhibitor and an angiotensin converting enzyme inhibitor. Also within the scope of this invention are pharmaceutical compositions for this method of use.

ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES

Substituted imidazoles such as STR1 are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure.

Treatment of central nervous system disorders with imidazole angiotensin-II receptor antagonists

Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole and pharmaceutically acceptable salts thereof are useful for treating central nervous system disorders, such as cognitive and learning disorders, mediated by angiotensin II.

Treatment of congestive heart failure with angiotensin 11 receptor blocking imidazoles

Substituted imidazoles such as STR1 are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure.

Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)imidazoles as Potent, Orally Active Antihypertensives

A new series of nonpeptide angiotensin II (AII) receptor antagonists has been prepared.These N-(biphenylylmethyl)imidazoles, e.g. 2-butyl-1--4-chloro-5-(hydroxymethyl)imidazole, differ from the previously reported N-(benzamidobenzyl)imidazoles and related compounds in that they produce a potent antihypertensive effect upon oral administration; the earlier series generally were active only when administered intravenously.It has been found that the acidic group at the 2'-position of the biphenyl is essential.Only ortho-substituted acids possess both high affinity for the AII receptor and good oral antihypertensive potency.The carboxylic acid group has been replaced with a variety of acidic isosteres, and the tetrazole ring has been found to be the most effective.The tetrazole derivative, DuP 753, is currently in development for the treatment of hypertension.